AU2013274389A1 - Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies - Google Patents

Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies Download PDF

Info

Publication number
AU2013274389A1
AU2013274389A1 AU2013274389A AU2013274389A AU2013274389A1 AU 2013274389 A1 AU2013274389 A1 AU 2013274389A1 AU 2013274389 A AU2013274389 A AU 2013274389A AU 2013274389 A AU2013274389 A AU 2013274389A AU 2013274389 A1 AU2013274389 A1 AU 2013274389A1
Authority
AU
Australia
Prior art keywords
ifn
type
patient
disorder
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013274389A
Other languages
English (en)
Inventor
Linda Chang
Brandon Higgs
Lorin Roskos
Bing Wang
Yihong Yao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013274389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of AU2013274389A1 publication Critical patent/AU2013274389A1/en
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB Request for Assignment Assignors: MEDIMMUNE, LLC
Priority to AU2018206851A priority Critical patent/AU2018206851C1/en
Priority to AU2020204613A priority patent/AU2020204613B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Databases & Information Systems (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Primary Health Care (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Mathematical Physics (AREA)
  • Computing Systems (AREA)
AU2013274389A 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies Abandoned AU2013274389A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018206851A AU2018206851C1 (en) 2012-06-13 2018-07-23 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
AU2020204613A AU2020204613B2 (en) 2012-06-13 2020-07-10 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
US61/659,138 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018206851A Division AU2018206851C1 (en) 2012-06-13 2018-07-23 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Publications (1)

Publication Number Publication Date
AU2013274389A1 true AU2013274389A1 (en) 2015-01-22

Family

ID=49758685

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013274389A Abandoned AU2013274389A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type I interferon receptor (IFNAR) antibodies
AU2018206851A Active AU2018206851C1 (en) 2012-06-13 2018-07-23 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
AU2020204613A Active AU2020204613B2 (en) 2012-06-13 2020-07-10 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018206851A Active AU2018206851C1 (en) 2012-06-13 2018-07-23 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
AU2020204613A Active AU2020204613B2 (en) 2012-06-13 2020-07-10 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Country Status (9)

Country Link
US (1) US9493570B2 (enExample)
EP (1) EP2861621A4 (enExample)
JP (5) JP2015526391A (enExample)
KR (3) KR102185237B1 (enExample)
CN (3) CN111494624A (enExample)
AU (3) AU2013274389A1 (enExample)
CA (1) CA2876636C (enExample)
HK (1) HK1209758A1 (enExample)
WO (1) WO2013188494A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5160887B2 (ja) * 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
US20180305761A1 (en) 2015-10-09 2018-10-25 Genefron Ltd. METHODS AND KITS FOR PREDICTION AND DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS (hCMV) CONGENITAL TRANSMISSION
DK3478830T3 (da) 2016-07-01 2024-05-21 Resolve Therapeutics Llc Optimerede binucleasefusioner og metoder
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
US20200031943A1 (en) 2017-03-21 2020-01-30 Austrianni Gmbh Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
US11139051B2 (en) * 2018-10-02 2021-10-05 Origent Data Sciences, Inc. Systems and methods for designing clinical trials
EA202191133A1 (ru) * 2018-10-26 2021-07-12 Янссен Байотек, Инк. Сигнатуры интерферона типа i и способы их применения
CN113728006B (zh) * 2019-01-31 2022-10-14 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法
MX2023012465A (es) * 2021-04-23 2024-04-04 Astrazeneca Ab Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
JP5160887B2 (ja) * 2004-06-21 2013-03-13 メダレックス インコーポレイテッド インターフェロンアルファレセプター１抗体及びその使用法
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2651866C (en) * 2006-05-11 2014-10-28 Universiteit Gent Sialoadhesin-related compositions and methods
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
RU2527068C2 (ru) * 2006-12-06 2014-08-27 Медиммун, Ллк Фармакодинамические маркеры, индуцированные интерфероном альфа
HUE025787T2 (en) * 2007-11-05 2016-05-30 Medimmune Llc Method for treating scleroderma
PL2250279T3 (pl) * 2008-02-08 2016-11-30 Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
NZ591137A (en) 2008-08-15 2012-10-26 Merrimack Pharmaceuticals Inc Methods and systems for predicting response of cells to a therapeutic agent
PT2473636T (pt) 2009-09-03 2017-02-06 Medimmune Llc Diagnóstico de interferão de tipo-1

Also Published As

Publication number Publication date
CN111494624A (zh) 2020-08-07
US9493570B2 (en) 2016-11-15
CA2876636A1 (en) 2013-12-19
JP2018065845A (ja) 2018-04-26
AU2018206851A1 (en) 2018-08-09
CA2876636C (en) 2022-09-13
AU2018206851B2 (en) 2020-07-30
AU2018206851C1 (en) 2021-11-25
KR102185237B9 (ko) 2021-08-06
EP2861621A1 (en) 2015-04-22
JP2015526391A (ja) 2015-09-10
JP2021167336A (ja) 2021-10-21
KR102185237B1 (ko) 2020-12-02
WO2013188494A1 (en) 2013-12-19
KR20200133395A (ko) 2020-11-27
CN104603152A (zh) 2015-05-06
HK1209758A1 (en) 2016-04-08
JP2019112429A (ja) 2019-07-11
JP6814238B2 (ja) 2021-01-13
US20150158949A1 (en) 2015-06-11
CN108310375A (zh) 2018-07-24
KR20210130270A (ko) 2021-10-29
JP7123225B2 (ja) 2022-08-22
JP2021042208A (ja) 2021-03-18
AU2020204613A1 (en) 2020-07-30
AU2020204613B2 (en) 2021-10-07
KR102320059B1 (ko) 2021-11-01
KR20150035825A (ko) 2015-04-07
EP2861621A4 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
AU2020204613B2 (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
JP6949009B2 (ja) ヒトプログラム死リガンド２（ｐｄ−ｌ２）に結合する抗体およびその用途
US20170121771A1 (en) Interferon alpha-induced pharmacodynamic markers and uses thereof
KR20180063127A (ko) Il23 경로 바이오마커를 사용한, il23-길항제에 대한 임상 반응의 예측
CN104011223A (zh) 使用il-17拮抗剂及psa应答或非应答等位基因治疗银屑病性关节炎(psa)的方法
JP2018042578A (ja) 中和抗ｃｃｌ２０抗体
EP3359688B1 (en) Molecular signatures for use in diagnosis and response to treatment analysis of autoimmune diseases
CA2686861A1 (en) Interferon alpha-induced pharmacodynamic markers
CA2836926A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
KR20180096633A (ko) Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
JP2025520063A (ja) ヒトｃｃｒ８に結合する抗体
TWI826839B (zh) CD1a抗體及其用途
HK40034632A (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ASTRAZENECA AB

Free format text: FORMER APPLICANT(S): MEDIMMUNE, LLC

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted